Bhupendra Tolia, MD
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,501 of the $3,226 with a category attached, or 77.5%. 19 manufacturers reported payments, led by Urovant Sciences Inc at 27.1% of the total. Reporting peaked in 2022 at $1,127 and has fallen 94.3% since, to $64 in 2025.
Across 74 payments — averaging $43.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Urovant Sciences Inc$873
- Pfizer$574
- Johnson & Johnson$489
- Sumitomo Pharma America, Inc.$407
- Astellas Pharma US Inc$169
- Idorsia Pharmaceuticals US Inc$125
- plus $588 from 13 others
Across 171 payments — averaging $1485.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$254K
What the payments were for
- Consulting fees$52516%
- Speaking & faculty fees$1254%
- Food & beverage$2,50178%
- Education$752%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Urovant Sciences Inc | 12 | $873 |
| Pfizer | 6 | $574 |
| Johnson & Johnson(2 entities) | 14 | $489 |
| Sumitomo Pharma America, Inc. | 13 | $407 |
| Astellas Pharma US Inc | 6 | $169 |
| Idorsia Pharmaceuticals US Inc | 2 | $125 |
| Teva Pharmaceuticals USA, Inc. | 1 | $125 |
| Amarin Pharma, Inc. | 1 | $103 |
| Myovant Sciences Inc. | 4 | $62 |
| Amgen | 3 | $55 |
| AbbVie | 2 | $46 |
| Taiho Oncology, Inc. | 2 | $34 |
| Merck | 1 | $31 |
| Myriad Genetic Laboratories, Inc. | 2 | $28 |
| Verity Pharmaceuticals Inc. | 1 | $25 |
| Seagen Inc. | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Teleflex LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,226 in reported general payments places this provider in the 55th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 13 | $428,105 |
| Lupron DepotLeuprolide Acetate | 44 | $294,213 |
| GemtesaVibegron | 82 | $74,694 |
| MyrbetriqMirabegron | 38 | $31,285 |
| ProcritEpoetin Alfa | 13 | $10,515 |
| Tamsulosin Hcl | 370 | $4,775 |
| Silodosin | 54 | $4,017 |
| Finasteride | 181 | $1,993 |
| Tolterodine Tartrate ErTolterodine Tartrate | 21 | $1,590 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 183 | $1,082 |
| Dutasteride | 29 | $999 |
| Doxazosin Mesylate | 44 | $855 |
| Oxybutynin Chloride ErOxybutynin Chloride | 55 | $798 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 25 | $774 |
| Solifenacin Succinate | 13 | $525 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLupron Depot | $46 | $294,21344 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $407 | $74,69482 claims |
| Astellas Pharma US IncMyrbetriq | $169 | $31,28538 claims |
| Johnson & JohnsonProcrit | $489 | $10,51513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 952 urology providers in New York.
Other urology in Bronx
- Pedro MariaBronx$242K
- Glen McWilliamsBronx$146K
- Lanna CheuckBronx$89K
- Peter WalterJamestown$1.9M
- Christopher PieczonkaSyracuse$797K
- Bilal ChughtaiNew York$658K
- Katie MurrayNew York$575K
- Neil BanderNew York$544K
- Robert ValenzuelaNew York$494K
- Jeffrey SpencerCheektowaga$430K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.